The Cancer Cell Biology and Therapeutics team is internationally acclaimed for pioneering research into the role of extracellular vesicles in cancer multidrug resistance and metastasis.
This novel research program investigates the role of these vesicles – sacs of functional proteins in nucleic acids and lipids – in cancer recurrence, with a particular emphasis on the development of drug resistance and metastasis in haematological and solid cancers.
The research team was the first in the world to demonstrate that these vesicles have an extraordinary ability to transfer deleterious cancer traits, such as multi-drug resistance and metastatic capacity, to healthy cells. New research has also highlighted the capacity of vesicles to alter biomechanical properties of tissue in recipient cells and to facilitate immune evasion and the establishment of the pre-metastatic niche.
In addition to identifying these mechanisms, researchers in this stream are defining the cellular basis of vesicle formation in order to develop novel therapeutics to target these transfer pathways. They are also exploring new liquid biopsy technologies that use vesicles as biomarkers. Outputs in this area have the potential to impact patients, practitioners and clinical practice.
Associate Professor Mary Bebawy
B Sc (Hons), PhD)
Associate Professor Bebawy is a world-leading cancer cell biologist and pharmaceutical scientist. Her work with extracellular vesicles has created a new field of cancer research.
She supervises research students in the areas of: Oncology, multi-drug resistance, pharmaceutical science, industrial R&D, cell biology.
Find out more about the Cancer Cell Biology and Therapeutics research team, including PostDocs, current doctoral students and their projects.
View the team's recent publications, projects, collaborations and other research output.